

Resource Summary Report

Generated by [dkNET](#) on Jul 30, 2026

InVivoMab anti-mouse PD-L1 (B7-H1)

RRID:AB_10949073

Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0101, RRID:AB_10949073)

Antibody Information

URL: http://antibodyregistry.org/AB_10949073

Proper Citation: (Bio X Cell Cat# BE0101, RRID:AB_10949073)

Target Antigen: PD-L1 (B7-H1)

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow Cytometry, Immunofluorescence, Immunohistochemistry, in vivo Neutralization & Blocking, Western Blot, in vitro Organoids/Organ-on-Chip
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:TRUE

Antibody Name: InVivoMab anti-mouse PD-L1 (B7-H1)

Description: This monoclonal targets PD-L1 (B7-H1)

Target Organism: mouse

Clone ID: clone 10F.9G2™

Antibody ID: AB_10949073

Vendor: Bio X Cell

Catalog Number: BE0101

Alternative Catalog Numbers: BE0101-100MG, BE0101-25MG, BE0101-50MG, BE0101-1MG, BE0101-5MG

Record Creation Time: 20260114T193156+0000

Record Last Update: 20260706T190413+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:FALSE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:TRUE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for InVivoMab anti-mouse PD-L1 (B7-H1).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 160 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Guo W, et al. (2026) Tumor-initiating stem cells fine-tune the plasticity of neutrophils to sculpt a protective niche. Cancer cell, 44(1), 94.

Li C, et al. (2025) Glutamate transporter SLC1A6 promotes resistance to immunotherapy in cancer. Cancer immunology, immunotherapy : CII, 74(8), 240.

Shao YY, et al. (2025) Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma. Biology direct, 20(1), 49.

Wang S, et al. (2025) ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy. Cell reports. Medicine, 6(9), 102336.

Valvo VM, et al. (2025) Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. Molecular cancer therapeutics, 24(6), 843.

Chen J, et al. (2025) Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. Cancer cell, 43(3), 361.

Mu H, et al. (2025) Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma. Cell reports. Medicine, 6(3), 101977.

- Zhang Y, et al. (2025) Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. *Cancer cell*, 43(3), 446.
- Yu H, et al. (2025) UDP-GlcUA triggers PKR kinase activity to promote liquid-liquid phase separation of TOP2A and enhances radioimmunotherapy resistance. *Molecular cell*, 85(21), 3913.
- Wang J, et al. (2025) The transcription factor ZEB2 mediates the antitumor efficacy of tumor-infiltrating lymphocytes in non-small cell lung cancer. *Cell death & disease*, 16(1), 806.
- Zhang Y, et al. (2025) Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance. *Cell*, 188(24), 6754.
- Hua D, et al. (2025) The combination of *Clostridium butyricum* and *Akkermansia muciniphila* mitigates DSS-induced colitis and attenuates colitis-associated tumorigenesis by modulating gut microbiota and reducing CD8⁺ T cells in mice. *mSystems*, 10(2), e0156724.
- Elder AM, et al. (2025) Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer. *Cell reports*, 44(5), 115676.
- Chen D, et al. (2025) DNASE1L3-expressing dendritic cells promote CD8⁺ T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps. *Cancer cell*, 43(9), 1758.
- Phelps CM, et al. (2025) Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy. *Cell*.
- Niu D, et al. (2025) Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors. *Cell reports. Medicine*, 6(10), 102413.
- He J, et al. (2025) Potentiating immunotherapy in "immune-cold" solid tumors through orchestrating T cell immunity via tumor-specific genetic engineering. *Cell reports. Medicine*, 6(12), 102510.
- Liu ZY, et al. (2025) Efflux of N1-acetylspermidine from hepatoma fosters macrophage-mediated immune suppression to dampen immunotherapeutic efficacy. *Immunity*, 58(6), 1572.
- Nie H, et al. (2025) Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. *Cancer research*, 85(18), 3471.
- Hirade K, et al. (2025) Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy. *Cell reports. Medicine*, 6(9), 102317.